<DOC>
	<DOCNO>NCT00536978</DOCNO>
	<brief_summary>Primary objective : - To determine safety adback T- Natural Killer ( NK ) cell patient lymphoid malignancy receive allogeneic stem cell transplantation Campath-IH contain condition regimen . Secondary objective : - To determine efficacy ( disease-free-survival ) strategy .</brief_summary>
	<brief_title>Natural Killer ( NK ) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx Patients With Lymphoid Malignancies</brief_title>
	<detailed_description>NK Cells , T-Cells , Study Drugs : NK T-cells donor may decrease risk relapse ( reappearance disease ) stem cell transplantation . NK cell T-cells kind white blood cell . Both type cell ability fight infection `` kill '' tumor cell body . NK cell call `` natural killer '' , unlike T-cells , NK cell need activate ( `` turn '' ) antigen ( foreign substance ) order `` attack '' `` kill '' tumor cell . Screening Tests : Before start treatment study , `` screening test '' perform help doctor determine eligibility take part study . - Physical exam . - Blood drawn ( 6 1/2 8 tablespoon ) routine test , check effect transplantation , liver function test . This routine blood draw also include pregnancy test woman able child . To eligible take part study , pregnancy test must negative . - Urine collect routine test . - Bone marrow biopsy perform check status disease . To collect bone marrow biopsy , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . - Chest x-ray , compute tomography ( CT ) scan , electrocardiogram ( ECG -- test measure electrical activity heart ) . Study Treatment : Treatment begin within 30 day screen visit . All study drug give central venous catheter ( CVC ) leave place throughout treatment . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , sign separate consent form procedure require Before start chemotherapy study , 21 day must elapse since last biological therapy , chemotherapy , radiotherapy , investigational therapy . PATIENTS RECEIVING BEAM , CAMPATH-IH , AND RITUXIMAB AS CONDITIONING : BEAM design kill leukemia lymphoma cell insert cell DNA ( genetic material cell ) . Alemtuzumab design attach foreign substance ( antigen ) find certain immune cell , may cause cell die . Rituximab design attach lymphoma cell , may cause die . On Day 1 , BCNU give 1 hour . On Days 2-5 , Ara-C give 1 hour etoposide 3 hour . This repeat every 12 hour 4 day . On Days 2-4 , alemtuzumab give 30 minute . Hydrocortisone tacrolimus give vein time help prevent ease side effect , chill , skin rash , and/or hive . On Day 6 , melphalan give 30 minute . Rituximab also give 5-7 hour , 13 day transplantation week total 4 dos . On Day 7 , completion chemotherapy , blood marrow stem cell collect earlier transplant ( give body ) CVC 30-45 minute . This standard treatment . On Days +1 , +3 , +6 stem cell infusion , methotrexate give vein help decrease risk graft-versus-host disease . G-CSF ( filgrastim ) inject skin day neutrophil ( type white blood cell ) count recover . About 60 patient take part study . All enrol M. D. Anderson . FOR PATIENTS RECEIVING FLUDARABINE , CYCLOPHOSPHAMIDE , CAMPATH-IH , RITUXIMAB , AND TBI : TBI design damage DNA ( genetic material cell ) cancer cell , may kill cancer cell . Alemtuzumab design attach foreign substance ( antigen ) find certain immune cell , may cause cell die . Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Fludarabine design make cancer cell less able repair damage DNA ( genetic material cell ) . This may increase likelihood cell die . Rituximab design attach lymphoma cell , may cause die . On Days 1-3 , alemtuzumab give 30 minute , fludarabine 1 hour , cyclophosphamide 1 hour . Hydrocortisone tacrolimus give vein time help prevent ease side effect , chill , skin rash , and/or hive . Rituximab also give 5-7 hour , 13 day transplantation week total 4 dos . On Day 5 , completion chemotherapy , TBI give , later day , blood stem cell collect earlier transplant ( give back body ) CVC 30-45 minute . This standard treatment . On Days +1 , +3 , +6 stem cell infusion , methotrexate give vein help decrease risk graft-versus-host disease . G-CSF ( filgrastim ) inject skin day neutrophil ( type white blood cell ) count recover . About 80 patient take part study . All enrol M. D. Anderson . ALL PATIENTS : Infusion NK Cells T-Cells : A `` boost '' NK cell T-cells donor may give blood stem cell transplantation , depend disease status amount donor cell blood . If complete remission ( disappearance cancer symptom ) achieve 3 month transplantation 80 % donor T-cells , additional T-cells give . If donor T-cells le 80 % blood , boost NK cell T-cells give . The type cell give depend result DNA test do screen visit check presence molecule may able activate ( `` turn '' ) NK cell specific area DNA . The type cell infusion may repeat 8 week later , percentage donor T-cells reach 100 % blood . If active disease persist 3 month transplantation , 1 dose rituximab give week , NK cell T-cells give second third dose rituximab . Infusion NK cell T-cells may repeat every 6 week ( 12 week ) , disease achieve complete remission first infusion cell . It require stay hospital 2 week transplantation 2-3 week transplantation . The additional cell infused outpatient basis . Epinephrine antihistamines available bedside NK cell infusion help treat allergic reaction . Study Visits : It require stay Houston area 100 day transplantation . During initial study visit , follow tests/procedures perform transplantation . - Blood transfusion blood platelet need . - Blood drawn ( 6 teaspoon ) routine test . - Blood drawn ( 6-10 tablespoon ) check effect transplantation . - Urine collect routine test . - Imaging scan , one perform screen visit . - Bone marrow biopsy perform , necessary . Between Days 25-35 transplantation , 3 month , CT scan , positron emission tomography ( PET ) , routine blood draw ( 6 teaspoon ) , bone marrow biopsy/aspirate perform . These test do check status disease . Length Study : Length time study 3 year , unless disease get bad intolerable side effect experience . Follow-up : After Day 35 , disease remission 100 % donor cell , evaluation perform every 3 month first year every 6 month 3 year . If disease remission Days 90-100 , CT scan , PET scan , routine blood test ( 6 teaspoon ) , bone marrow biopsy/aspirate perform every 6-8 week ( NK T-cell infusion remission achieve ) . Then , test repeat every 6 month . This investigational study . All drug use study FDA approve commercially available . The use NK cell FDA approve commercially available . The use drug NK cell together study investigational .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Up 70 year age . 2 . Bcell lymphoid malignancy ( CD20 negative disease diagnosis receive rituximab ) : This include CLL/small lymphocytic lymphoma , follicular lymphoma , mantle cell , diffuse large cell , Splenic lymphoma , MucosaAssociated Lymphoid Tissue ( MALT ) , lymphoplasmacytic lymphoma Burkitt 's lymphoma . 3 . Patients relapse consider high risk relapse . 4 . In order increase chance KIRmismatching recipient donor , 9/10 match ( mismatched locus C ) unrelated donor would preferable . If mismatch donor available , fullymatched unrelated donor 9/10 match unrelated donor consider . 5 . A sibling donor 9/10 matched may also allow . 6 . Zubrod PS &lt; /= 2 . 7 . Left ventricular ejection fraction ( LVEF ) &gt; /= 40 % uncontrolled arrythmias symptomatic heart disease . 8 . Forced expiratory volume one second ( FEV1 ) , Forced Expiratory Volume ( FVC ) Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; /= 50 % . 9 . Serum creatinine &lt; 1.8 mg/dL . Serum bilirubin &lt; 3 * upper limit normal , 10 . Aspartate aminotransferase ( AST ) &lt; 3 * upper limit normal . 11 . Signed , write Internal Review Board ( IRB ) approve informed consent . 12 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 1 . Past history anaphylaxis follow exposure CAMPATHIH Rituximab 2 . Patient active Central Nervous System ( CNS ) disease . 3 . Positive Beta human chorionic gonadotrophin ( hCG ) text woman child bear potential define postmenopausal 12 month previous surgical sterilization , currently breastfeed . 4 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 5 . Patients malignancy diagnose within 2 year prior Study registration ( except skin squamous cell carcinoma ) . 6 . Active uncontrolled bacterial , viral fungal infection . 7 . Major surgical procedure significant traumatic injury within 4 week prior Study registration . 8 . Serious , nonhealing wound , ulcer , bone fracture . 9 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Study registration . 10 . History Stroke within 6 month . 11 . Myocardial infarction within past 6 month prior Study registration . 12 . Uncontrolled chronic diarrhea . 13 . A prior allogeneic transplant donor . Is age limit ? Yes</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>B-Cell Lymphoid Malignancies</keyword>
	<keyword>CLL</keyword>
	<keyword>Cll/Small Lymphocytic Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Diffuse Large Cell Lymphoma</keyword>
	<keyword>Splenic Lymphoma</keyword>
	<keyword>MALT</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>ARA-C</keyword>
	<keyword>BCNU</keyword>
	<keyword>Campath-1H</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
	<keyword>T-Cell Cell Adback</keyword>
	<keyword>Natural Killer ( NK ) Cell Adback</keyword>
</DOC>